NeoStem (AMEX: NBS) PCT Subsidiary receives Accreditations

Apr. 13, 2011 12:35 PM ET

120 Followers

Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.

http://www.regmedinvestors.com

Long/Short Equity, Special Situations, Contrarian

Seeking Alpha Analyst Since 2009

Editor and Publisher ... Henry enters his thirteen (13) year at RegMed Investors which aggregates, curates and creates bottom-line content of regenerative medicine - stem, gene and cell therapy news providing a "vetted" selection of relevant and high-impact synthesis. He was VP - Strategic Planning and Communication at Curis (2001-2002), HQCM focusing on healthcare investments (NYSE:HQH/HQL) from (1985-2001)and founded LifeScience Economics, a healthcare research and analytics firm with offices in Boston, MA and Palo Alto, CA. Past experiences include Thermo Scientific, SWEC following 5 years at the FBI. A former military officer, Henry has been an adjunct professor at Boston University and Golden Gate University where he taught courses in venture capital, corporate finance and strategic development in the universities' graduate business schools.

NBS’s Progenitor Cell Therapy (PCT), a wholly owned subsidiary is in compliance with FACT-JACIE based on inspections at facilities in Allendale, New Jersey and Moutain View, Cal

FACT-JACIE standards were developed in 2006 by the Foundation for the Accreditation of Cellular Therapy and the Joint Accreditation Committee of the International Society for Cellular Therapy (ISCT) and the European Group for Blood and Marrow Transplantation (EBMT).

The Bottom Line: The accreditation process involved the submission of documentation to demonstrate compliance to standards and subsequent on-site inspections conducted by inspectors qualified by training and experience in cellular therapy. Adherence to such high standards further ensures cell stability and viability and batch consistency for the development of a cell therapy product. PCT also obtained AABB accreditation in the category of “Cord Blood Activities Processing, Storage and Distribution” for its NJ facility. With plans to rapidly expand the manufacturing and storage business to drive revenues from cell therapy clients as well as internal therapeutic development, FACT accreditation for PCT is critical to promote quality medical and laboratory practice of cellular therapy through its peer-developed standards and voluntary inspection and accreditation program. AMEX: NBS is up $0.04 (2.05%) to $1.99 in early morning trading.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Recommended For You